This study is in progress, not accepting new patients
An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startestimated completion
- Principal Investigator
- by Jennie Taylor
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jennie Taylor
Associate Professor, Neurology, School of Medicine. Authored (or co-authored) 68 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bristol-Myers Squibb
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls Investigator Inquiry Form
- ID
- NCT02667587
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 716 people participating
- Last Updated